Six banking lines, from structure to the bell

Step one: can your financials be audited at all

This is the shared precondition of every route, and the one most often skipped. Revenue recognition, related-party transactions, share-based payments and off-book cash flows for the last two to three fiscal years — if any of them cannot be restated under US GAAP, the choice between IPO and reverse merger is irrelevant, because a reverse merger requires a PCAOB audit too, and a further one at uplisting. The first question is never which route is faster. It is whether the financial base qualifies.

Step two: are you buying speed or valuation

A traditional IPO takes longer and costs more, but it raises capital at listing, brings an underwriter's endorsement and an institutional shareholder base. A reverse merger is fast but normally raises no new money, and the cleanliness of the shell determines whether you can ever uplist. A SPAC sits between the two: the merger is the listing and capital is already in trust, but the dilution and sponsor incentive terms are complex and can consume a large share of equity if negotiated badly. The trade is time for valuation, or valuation for time.

Step three: are you missing a route or a team

Route questions — which path, where the shell comes from, how a SPAC is sponsored — sit on the banking side. Team questions — who is CFO, who signs off SOX 404, who answers institutional questions on the roadshow — sit on the staffing side. Most China-based issuers are short of both at once: no settled route, and no finance lead who can speak to US institutions. Solve only half and the project stalls in the middle.

US IPO: audit positions and the completeness of the first filing

An audit is not "issuing a report". It is reconciling three sets of books into one set that survives PCAOB inspection. Nominee shareholdings, the fair value of employee options, related-party fund flows, the timing of government grant recognition — if any one lacks supporting documents, the auditor does not sign. And an incomplete first S-1 / F-1 turns two or three comment rounds into five or six, at one to two months each.

Reverse merger: shell quality and uplisting conditions

A cheap shell is not a usable shell. What has to be checked: undisclosed liabilities and litigation, whether the original shareholders have been cleared out, whether the OTC quotation is still active, and whether the entity falls under the SEC's definition of a shell company, which triggers extra disclosure obligations. More important is uplisting — an OTC ticker is not a Nasdaq listing. Uplisting requires the exchange's price, public float, shareholder-count and market-maker conditions. Miss them and the shell sits on OTC indefinitely.

Shell transactions: scope of diligence and closing mechanics

Buying a shell is an acquisition. Beyond legal and financial diligence, you need to settle the control transfer mechanism (share transfer or new issuance), the dilution retained by existing holders, and who carries historical disclosure liability after closing. The trap is not the price. It is the terms.

SPAC: sponsor promote and redemption rates

The cost of a SPAC is not on the surface. Roughly 20% promote shares held by the sponsor, underwriting and trust fees, and the redemption right of existing shareholders at merger stack up and materially dilute the target's shareholders. In weak markets redemptions run high, most of the trust is withdrawn, and cash at closing lands far below the headline raise. SPACs are not dead — but the arithmetic has to be done on post-redemption cash.

SEC reporting and post-listing compliance: the first 10-K and SOX 404

Listing is the start. The first annual report has to be produced under US GAAP inside a very tight window, and internal controls have to pass 404 testing in year one. Many companies are carried through the IPO by advisers who then leave, and the in-house team cannot hold it. That is when mistakes cost most — the company is already public, and a correction is itself a material event.

Follow-on financing: valuation maintenance after listing

Whether you can raise again depends on continuous investor relations and predictable earnings communication. Companies that go quiet after listing find that institutions do not negotiate on price at the second raise. They simply do not take the meeting.

Group one: fixed costs, independent of deal size

• Audit — a PCAOB-registered firm, priced on scope and number of historical years, not on proceeds;
• US counsel — drafting and amending the prospectus, responding to comments;
• PRC counsel and restructuring — red-chip or VIE build-out, SAFE registration, tax clean-up;
• Internal controls and SOX 404 readiness — process mapping, systems work, testing evidence;
• Printing and translation, depositary set-up, initial listing fee — comparatively fixed.

Group two: costs that move with the raise

• Underwriting fee — normally a percentage of proceeds, and the largest variable item;
• Roadshow and investor relations — priced by city and session count;
• Annual listing fee — tiered by shares outstanding, payable every year after listing.

So the right question is not "what does a listing cost" but "how much is fixed, and what is the underwriting percentage". The fixed part decides whether you can start; the percentage decides how much you give away. Small raises are where this bites: spread a fixed cost base over a small deal and the ratio becomes absurd — which is precisely why Nasdaq's 2026 rule lifts the firm-commitment threshold to the US$25 million level. Small offerings are uneconomic for issuer and market alike.